MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on August 23, 2007; DOI: 10.1124/mol.107.035337


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.035337v1
72/5/1359    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sato, M.
Right arrow Articles by Summers, R. J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sato, M.
Right arrow Articles by Summers, R. J


Received for publication February 26, 2007.
Revised August 22, 2007.
Accepted for publication August 22, 2007.

Ligand-directed signaling at the {beta}3-adrenoceptor produced by SR59230A relative to receptor agonists

Masaaki Sato 1, Takahiro Horinouchi 2, Dana S Hutchinson 1, Bronwyn Anne Evans 1, Roger J Summers 1*

1 Monash University 2 Hokkaido University

* Address correspondence to: E-mail: roger.summers{at}med.monash.edu.au

Abstract

This study examines signaling pathways activated by the mouse {beta}3-adrenoceptor (AR) expressed in Chinese hamster ovary cells at high (CHO{beta}3H) or low (CHO{beta}3L) levels. Functional responses included extracellular acidification rate (ECAR), cyclic AMP accumulation, and p38 MAPK or Erk1/2 phosphorylation. (-)-Isoproterenol and the {beta}3-AR agonist CL316243 caused concentration-dependent increases in cAMP accumulation and ECAR in CHO{beta}3H and CHO{beta}3L cells. For cAMP accumulation, the {beta}3-AR ligand SR59230A was a partial agonist in CHO{beta}3H and an antagonist in CHO{beta}3L cells but for ECAR was an agonist at both expression levels. This suggested that SR59230A which is normally regarded as an antagonist can selectively activate pathways leading to ECAR. Examination of the pathways stimulated by (-)-isoproterenol, CL316243 and SR59230A for both ECAR and cAMP accumulation suggested that the cAMP pathway predominates in CHO{beta}3H cells while p38 MAPK is a major contributor to ECAR in CHO{beta}3L cells and was the sole contributor to responses to SR59230A. Western blots of p38 MAPK and Erk1/2 phosphorylation confirmed that MAPKs are activated in CHO{beta}3H and CHO{beta}3L cells by CL316243 and SR59230A but that SR59230A has much higher efficacy. In addition, p38 MAPK phosphorylation displayed differences in drug potency and efficacy between CHO{beta}3H and CHO{beta}3L cells related to inhibition of the response by cAMP. Thus CL316243 and SR59230A display reversed orders of efficacy for cAMP accumulation compared to Erk1/2 and p38 MAPK phosphorylation providing a strong indication of ligand-directed signaling.


Key words: Adrenergic, cAMP, MAP Kinase, P38 MAP Kinase


This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
M. Sato, D. S. Hutchinson, B. A. Evans, and R. J. Summers

Mol. Pharmacol., November 1, 2008; 74(5): 1417 - 1428.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. C. Michel and A. E. Alewijnse
Ligand-Directed Signaling: 50 Ways to Find a Lover
Mol. Pharmacol., November 1, 2007; 72(5): 1097 - 1099.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics